Article
The FDA has approved extended-release darifenacin (Enablex, 7.5 mg and 15 mg) for the treatment of overactive bladder.
Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation
Key updates from the AUA/ASRM male infertility guideline amendment
Ra223 plus SABR does not delay progression of oligometastatic HSPC
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT